FIELD: chemistry.
SUBSTANCE: invention relates to tripeptide compounds of general formula (1), where AA1 is selected from Lys, Orn, Nle, Phe, Nα-methyl-Phe, Nα,Nαdimethyl-Nle, Nα,Nαdimethyl-Phe and Nα,Nαdimethyl-Lys; and AA2 selected from α-aminoisobutyric acid (Aib), tert-butylglycine, amide α-aminoisobutyric acid, Nα-methyl-Thr-OH, Nα-methyl-Thr-NH2 and Nαmethyl-Val-OH, and their use as medications, in particular as anti-inflammatory agents.
.
EFFECT: object of the present invention is the provision of such compounds with increased stability and improved bioavailability being at the same time safe and secure for the patients.
8 cl, 6 dwg, 9 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
ALPHA-MELANOTROPIN PEPTIDE ANALOGUES | 2009 |
|
RU2496786C2 |
COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 | 2017 |
|
RU2733886C2 |
USE OF STIMULANT FOR ANALYZING ACTIVITY OF IMMUNE CELLS | 2020 |
|
RU2822517C2 |
METHOD FOR TREATING AUTOIMMUNE DISEASES USING TYPE 1 INTERFERONS | 1995 |
|
RU2166959C2 |
THERAPEUTIC AGENT FOR INHIBITION OF PHOSPHODIESTERASE AND ASSOCIATED PATHOLOGICAL DISORDERS | 2018 |
|
RU2815010C2 |
ALPHA- AND GAMMA-MSH ANALOGUES | 2013 |
|
RU2668791C2 |
TREATMENT | 2009 |
|
RU2554801C2 |
FUNCTIONALIZED SACCHARIDES AS ANTI-INFLAMMATORY AGENTS | 2018 |
|
RU2772214C2 |
NOVEL SYNTHETIC PEPTIDES AND USE THEREOF | 2012 |
|
RU2596393C2 |
AGONISTS OF NICOTINE RECEPTORS IN TREATMENT OF INFLAMMATORY DISEASES | 2002 |
|
RU2299731C2 |
Authors
Dates
2018-10-17—Published
2014-09-23—Filed